Cellectis Publishes Manuscript in Frontiers Bioengineering and Biotechnology

NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) — Cellectis (the “Company”) (Euronext Growth: ALCLS – NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today published a manuscript in Frontiers Bioengineering and Biotechnology demonstrating the feasibility of efficient multiplex gene engineering using a combination of two

Introduction

Cellectis, a leading biotechnology company, has made a significant breakthrough in the field of gene engineering. The company’s innovative approach utilizes a combination of two techniques to achieve efficient multiplex gene editing, as detailed in their recent publication in Frontiers Bioengineering and Biotechnology.

Background

Gene editing has emerged as a powerful tool in the development of novel therapies for a wide range of diseases. By precisely modifying genes, researchers can potentially treat genetic disorders and other illnesses at their root cause. Cellectis has been at the forefront of this technology, pioneering new methods to enhance the efficiency and accuracy of gene editing.

Key Findings

The manuscript published by Cellectis demonstrates the successful use of a combination of two gene-editing techniques to achieve multiplex gene engineering. This approach has shown promising results in preclinical studies, paving the way for potential advancements in the development of cell and gene therapies.

Impact

The implications of Cellectis’s research are far-reaching. By improving the efficiency of gene editing, the company is opening up new possibilities for the treatment of a variety of diseases. This could lead to more effective therapies and better outcomes for patients in need of life-saving interventions.

Conclusion

Cellectis’s publication in Frontiers Bioengineering and Biotechnology marks a significant milestone in the field of gene editing. The company’s innovative approach to multiplex gene engineering has the potential to revolutionize the development of cell and gene therapies, offering hope to patients around the world.

How this will affect me

Cellectis’s breakthrough in gene engineering could have a profound impact on individuals who are suffering from genetic disorders or other diseases. The development of more efficient gene-editing techniques could lead to the creation of new therapies that offer improved treatment options and better outcomes for patients.

How this will affect the world

The advancement of gene-editing technology by Cellectis has the potential to transform the field of medicine on a global scale. By increasing the efficiency and accuracy of gene editing, the company’s research could pave the way for the development of innovative therapies that address a wide range of health issues, ultimately improving the quality of life for people around the world.